Table 3 Expenditure on the top 10 orphan medicinal products (by total cost) for the periods 2009/10–2019/20, and 2014/15–2019/20
From: Costs of orphan medicinal products: longitudinal analysis of expenditure in Wales
Expenditure 2009/10 to 2019/20a | Expenditure 2014/15 to 2019/20 | ||||
|---|---|---|---|---|---|
Orphan medicine | Cost (£) | (% total orphan spend) | Orphan medicine | Cost (£) | (% total orphan spend) |
lenalidomide | 49,997,279 | 13.29 | eculizumab | 48,037,137 | 15.00 |
eculizumab | 48,060,011 | 12.78 | lenalidomide | 36,455,658 | 11.39 |
ivacaftor | 34,026,894 | 9.05 | ivacaftor | 32,887,314 | 10.27 |
imatinib mesilate | 26,171,612 | 6.96 | imatinib mesilate | 18,411,191 | 5.75 |
sunitinib malate | 18,899,422 | 5.02 | ibrutinib | 12,053,813 | 3.77 |
nilotinib | 13,092,369 | 3.48 | nilotinib | 11,401,227 | 3.56 |
azacitidine | 12,976,966 | 3.45 | azacitidine | 9,922,398 | 3.10 |
ibrutinib | 12,053,813 | 3.20 | sunitinib malate | 8,376,401 | 2.62 |
romiplostim | 8,052,131 | 2.14 | daratumumab | 7,614,869 | 2.38 |
daratumumab | 7,614,869 | 2.02 | romiplostim | 6,659,175 | 2.08 |